

Malawi

Support for Vaccine: Rotavirus

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Malawi							
2. Vaccine grant number: 1214-MWI-13B-X, 1516-MWI-13b-X, 1720-MWI-13b-X							
3. Date of Decision Letter: 10 September 2019							
4. Date of the Partnership Framework Agreement: 29 October 2013							
5. Programme title: New Vaccine Support (NVS), Rotavirus, Routine							
6. Vaccine type: Rotavirus							
7. Requested product presentation and formulation of vaccine: RV1, 1 dose/plastic tube, liq							
8. Programme Duration: ¹ 2012-2020							
9. Programme Budget (indicative): ² (subject to the terms of the Partnership Framework Agreement, if applicable)							
	2012-2018	2019	2020	2021	2022	2023	Total ²
Programme Budget (US\$)	17,349,048	3,415,500	3,199,500	-	-	-	23,964,048
10. Vaccine introduction grant A VIG of US\$611,500 was disbursed on 30/01/2012 and 27/08/2012							
11. Product switch grant Not applicable							
12. Indicative Annual Amounts: ³ (subject to the terms of the Partnership Framework Agreement, if applicable)							
Type of supplies to be purchased with Gavi funds	2012-2018		2019				
Number of vaccine doses			1,473,000				
Annual Amounts (US\$)	17,349,048		3,415,500				

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.														
14. Self-procurement:	Not applicable														
15. Co-financing obligations:	<p>According to the co-financing policy, the Country falls within the group: Initial self-financing</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2019</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>139,500</td> </tr> <tr> <td>Number of AD syringes</td> <td>-</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>-</td> </tr> <tr> <td>Number of safety boxes</td> <td>-</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>313,371</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>322,500</td> </tr> </tbody> </table>	Type of supplies to be purchased with Country funds in each year	2019	Number of vaccine doses	139,500	Number of AD syringes	-	Number of re-constitution syringes	-	Number of safety boxes	-	Value of vaccine doses (US\$)	313,371	Total co-financing payments (US\$) (including freight)	322,500
Type of supplies to be purchased with Country funds in each year	2019														
Number of vaccine doses	139,500														
Number of AD syringes	-														
Number of re-constitution syringes	-														
Number of safety boxes	-														
Value of vaccine doses (US\$)	313,371														
Total co-financing payments (US\$) (including freight)	322,500														
16. Operational support for catch-up campaigns:	Not applicable														
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines; Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> <p>31 March</p> <p>15 May</p> </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>		Due dates	<p>To prepare for the annual procurement of vaccines; Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March</p> <p>15 May</p>	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat								
	Due dates														
<p>To prepare for the annual procurement of vaccines; Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March</p> <p>15 May</p>														
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat														

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

Signed by,

On behalf of Gavi



Thabani Maphosa,

Managing Director, Country Programmes

10 September 2019